Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (22637)	12/23/1999 2:25:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

Frostman...PW issued another update on VVUS 12/23/99 est y2000 revenue from Muse up 15% target revenue for y2000 $30 mill..plenty of cash on hand and cash flow to feed works in progress in the R&D pipeline. Target price $7..will re-evaluate if/when VVUS has a sales partner. The shorts have to be getting the picture that VVUS is here to stay....and has great potential in Y2001 with new products under development. I believe they will also re-evaluate as Alibra receives final FDA approval and VVUS starts producing Alibra later in Y2000. THe real fun will be reading the Y2001 earnings forcast which could include PE oral drug and Female cream...as we get closer VVUS will fly higher. In for the long haul Y2000 and Y2001.